The global erythropoietin drugs market is expected to grow at a CAGR of around 5.8% from 2020 to 2027 and expected to reach the market value of around US$ 14.2 Bn by 2027.
The kidney produces erythropoietin (EPO), which is used to make red blood cells. Erythropoietin-stimulating agents are frequently used to treat people with chronic kidney disease and anemia. EPO, which is produced naturally by the kidneys, is also available as a pharmaceutical. EPO stimulates red blood cell production in bone marrow and regulates the concentration of red blood cells and hemoglobin in the blood. This is advantageous for athletes because red blood cells transport oxygen to cells, including muscle cells, allowing them to function more effectively.
Big calls for "Recombinant Erythropoietin Stimulating Agents"
When transfusions are not an option, such as when the patient is unable to or refuses a transfusion, recombinant erythropoietin may be administered. Recombinant erythropoietin is a synthetic version of naturally occurring erythropoietin. It is created by cloning the erythropoietin gene. Erythropoietin-stimulating agents are recombinant erythropoietin drugs (ESAs). These drugs are administered via injection (shot) and work by increasing the production of red blood cells. These cells are then released into the bloodstream from the bone marrow. There are two ESAs on the market in the United States: epoetin alfa (Procrit,® Epogen®) and darbepoietin alfa (Aranesp®). ESAs are typically prescribed to patients with chronic (long-term) kidney disease or end-stage renal (kidney) disease. Because they can't produce enough erythropoietin, these patients usually have low hemoglobin levels. ESAs are also prescribed to cancer patients. Anemia is common in these patients, which can be caused by chemotherapy.
Rising prevalence of anemia in patients propel the demand for erythropoietin drugs worldwide
Anemia is a condition in which the number of red blood cells or the concentration of hemoglobin within them is less than normal. Anemia is a serious global public health issue that disproportionately affects children and pregnant women. According to the World Health Organization (WHO), 42% of children under the age of five and 40% of pregnant women worldwide are anemic. Correcting anaemic conditions in the patient group necessitates increasing Hb, and correcting anemia necessitate improving platelet function. Epoetin may also be used to prevent or treat anemia caused by surgery or medications (for example, zidovudine) used to treat other conditions such as HIV or cancer.
Commercialization of Erythropoietin biosimilars bolsters the growth of global market
Biosimilar epoetins were approved for the first time in 2007, and a wealth of data has been accumulated over the last decade. So far, the EMA has approved two biosimilar epoetins (fewer than five different commercial names). These agents are approved only if extensive analytical and clinical testing demonstrates that they are of comparable quality, safety, and efficacy to the reference medicine, and real-world studies provide additional evidence that biosimilar epoetins are an effective and well-tolerated option for the treatment of chemotherapy-induced anemia in cancer patients. Furthermore, in May 2018, the United States Food and Drug Administration approved "Retacrit (epoetin alfa-epbx)" as a biosimilar to "Epogen/Procrit (epoetin alfa)" for the treatment of anemia caused by chronic kidney disease, chemotherapy, or zidovudine use in HIV patients. Retacrit is also approved for use before and after surgery to reduce the likelihood of needing red blood cell transfusions due to blood loss during surgery.
Impact of COVID-19 on global erythropoietin drugs market
The COVID-19 outbreak has disrupted workflows in the health care sector around the world. The disease has forced a number of industries, including several sub-domains of health care, to temporarily close their doors. However, there has been a positive impact and increase in demand for various medical services, including erythropoietin. According to researchers at the Max Planck Institute of Experimental Medicine in Göttingen, erythropoietin (EPO) is a drug for anemia and can be effective against COVID-19. They claim that when SARS-CoV-2 attacks the brain, the growth aspect of erythropoietin can prevent serious disease development and protect people from long-term neurological effects. Primary case studies indicate that erythropoietin has a beneficial effect. Scientists are currently planning a randomised clinical trial to systematically investigate the effects of using erythropoietin to treat COVID-19.
The global erythropoietin drugs market is segmented as drug class, product, and application. The drug class is classified into biologics and biosimilars. Based on product, the market is segregated as epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. By application, the market is segmented as cancer, hematology, renal diseases, and neurology.
Based on drug class segmentation, the biologics erythropoietin class is expected to dominate the global erythropoietin drugs market. This is because patents are protected. Another factor contributing to its dominance is the presence of a large patient population and a higher uptake of biologics. Due to the recent patent expiration of major brands such as Epogen, the biologics segment is expected to lose market share. This drug's patent exclusivity expired in May 2015, resulting in lower sales revenue for its manufacturer, Amgen Inc.
Epoetin-alfa has a reasonable market share in the global erythropoietin drugs market. Furthermore, there is a high usage rate in alleviating anemia in cancer and chronic renal failure patients. This was the first biologic to be approved by the US Food and Drug Administration for the treatment of anemia caused by CKD, cancer chemotherapy, and HIV treatment. Epoetin-alfa was patent-protected, limiting the production of any other recombinant human erythropoietin drug and assisting this segment to dominate in 2016.
Renal diseases have dominated the application market in the past and are expected to do so again during the forecast period. This is due to quick product approvals by authorised bodies. For example, the first erythropoietin drug, Epogen, was approved by the US Food and Drug Administration for the treatment of anaemic indications associated with CKD.
North America dominates; Asia Pacific records fastest growing CAGR for the global erythropoietin drugs market
The market for erythropoietin drugs is dominated by North America. The rising prevalence of chronic diseases such as cancer, chronic kidney disease (CKD), and HIV drives the demand for erythropoietin drugs. This is one of the major factors driving the growth of the global erythropoietin drugs market.
Asia Pacific, on the other hand, is expected to have the fastest growing CAGR in the coming years. This is due to the ongoing rise in the incidence of chronic diseases, as well as the high demand for low-cost therapeutics. Asia Pacific has sparked significant interest in many companies for the development of biosimilars, and the region is known for producing more biosimilars than any other region in the world.
The prominent players of the global erythropoietin drugs market involve Johnson & Johnson, Celltrion, Teva Pharmaceutical Industries Ltd., Amgen, Inc., F. Hoffmann-La Roche Ltd, LG Life Sciences Ltd., Biocon Limited, and among others
Market By Drug Class
Market By Product
Market By Application
Erythropoietin drugs market is expected to reach a market value of around US$ 14.2 Bn by 2027.
The erythropoietin drugs market is expected to grow at a CAGR of around 5.8% from 2020 to 2027.
Based on product, Epoetin-alfa segment is the leading segment in the overall market.
Commercialization of Erythropoietin biosimilars is one of the prominent factors that drive the demand for erythropoietin drugs market
Johnson & Johnson, Celltrion, Teva Pharmaceutical Industries Ltd., Amgen, Inc., F. Hoffmann-La Roche Ltd, LG Life Sciences Ltd., Biocon Limited, and among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years